SHR-1701

• UNSPSC Description:

  SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research[1].

• Target Antigen:

  PD-1/PD-L1; TGF-β Receptor

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Immunology/Inflammation;TGF-beta/Smad

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/shr-1701.html

• Purity:

  99.77

• Solubility:

  10 mM in DMSO

• Smiles:

  S[R1701]

• Molecular Weight:

  33.07

• References & Citations:

  [1]Bo Cheng, et al. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. Cancer Commun (Lond). 2022 Jan;42(1):17-36.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Phase 3

• CAS Number:

  2891860-17-4